Cargando…

High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia

The bone marrow microenvironment is known to provide a survival advantage to residual acute myeloid leukemia cells, possibly contributing to disease recurrence. The mechanisms by which stroma in the microenvironment regulates leukemia survival remain largely unknown. Using reverse-phase protein arra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Zhihong, Liu, Wenbin, Tsao, Twee, Qiu, YiHua, Zhao, Yang, Samudio, Ismael, Sarbassov, Dos D., Kornblau, Steven M., Baggerly, Keith A., Kantarjian, Hagop M., Konopleva, Marina, Andreeff, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685227/ https://www.ncbi.nlm.nih.gov/pubmed/28659338 http://dx.doi.org/10.3324/haematol.2016.162230

Ejemplares similares

Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy
por: Kadia, Tapan Mahendra, et al.
Publicado: (2019)

Mitochondrial Uncoupling and the Reprograming of Intermediary Metabolism in Leukemia Cells
por: Vélez, Juliana, et al.
Publicado: (2013)

Low Expression Of PP2A Regulatory Subunit B55α Is Associated With T308 Phosphorylation Of AKT And Shorter Complete Remission Duration In Acute Myeloid Leukemia Patients
por: Ruvolo, Peter P., et al.
Publicado: (2011)

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia
por: Khan, Maliha, et al.
Publicado: (2017)

Acute myeloid leukemia: current progress and future directions
por: Kantarjian, Hagop, et al.
Publicado: (2021)

Phosphorylation of GSK3α/β correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients
por: Ruvolo, Peter P., et al.
Publicado: (2015)

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
por: Jabbour, Elias, et al.
Publicado: (2010)

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
por: Morita, Kiyomi, et al.
Publicado: (2020)

Suboptimal Responses in Chronic Myeloid Leukemia
por: Jabbour, Elias, et al.
Publicado: (2012)

Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34(+) proliferating and quiescent chronic myeloid leukemia blast crisis cells
por: Carter, Bing Z., et al.
Publicado: (2015)

Development and targeted use of nilotinib in chronic myeloid leukemia
por: Fava, Carmen, et al.
Publicado: (2009)

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
por: Hochhaus, Andreas, et al.
Publicado: (2013)

MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells
por: Zeng, Zhihong, et al.
Publicado: (2016)

Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival
por: Kornblau, Steven M., et al.
Publicado: (2018)

Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
por: Morita, Kiyomi, et al.
Publicado: (2020)

Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
por: Morita, Kiyomi, et al.
Publicado: (2021)

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
por: Short, Nicholas J., et al.
Publicado: (2019)

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
por: Boddu, Prajwal, et al.
Publicado: (2018)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics
por: Pellegrino, Maurizio, et al.
Publicado: (2018)

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia
por: Briski, Robert, et al.
Publicado: (2023)

The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
por: Williams, Patrick, et al.
Publicado: (2018)

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
por: Issa, Ghayas C., et al.
Publicado: (2021)

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
por: George, Binsah, et al.
Publicado: (2021)

Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Barakos, Georgios Petros, et al.
Publicado: (2022)

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
por: Daver, Naval, et al.
Publicado: (2017)

Surface Adjustment of Reverse Phase Protein Arrays using Positive Control Spots
por: Neeley, E. Shannon, et al.
Publicado: (2012)

Immunotherapy in Acute Myeloid Leukemia: Where We Stand
por: Isidori, Alessandro, et al.
Publicado: (2021)

Prospective Analysis: Relative Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Era of Tyrosine Kinase Inhibitors
por: Sasaki, Koji, et al.
Publicado: (2015)

Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia
por: Jacamo, Rodrigo, et al.
Publicado: (2017)

Concurrent inhibition of IDH and methyltransferase maximizes therapeutic efficacy in IDH mutant acute myeloid leukemia
por: Zeng, Zhihong, et al.
Publicado: (2021)

Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
por: Konopleva, Marina, et al.
Publicado: (2022)

In vivo genome-wide CRISPR screening in murine acute myeloid leukemia uncovers microenvironmental dependencies
por: Mercier, Francois E., et al.
Publicado: (2022)

Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE‐A study
por: Jonas, Brian A., et al.
Publicado: (2022)

Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport
por: Velez, Juliana, et al.
Publicado: (2016)

Management of chronic myeloid leukemia in 2023 – common ground and common sense
por: Senapati, Jayastu, et al.
Publicado: (2023)

Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities
por: Huang, Xiao, et al.
Publicado: (2017)

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models
por: Han, Lina, et al.
Publicado: (2020)

Preclinical activity of the novel B‐cell‐specific Moloney murine leukemia virus integration site 1 inhibitor PTC‐209 in acute myeloid leukemia: Implications for leukemia therapy
por: Nishida, Yuki, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_h3skddflmn0hk95t4tp4vmha98